ReviewThe Journal of clinical endocrinology and metabolism2023
Screening and Prevention of Type 1 Diabetes: Where Are We?
Review in The Journal of clinical endocrinology and metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Novel Approach for Assessing Outcomes of Type 1 Diabetes Prevention Trials Over a Fixed Time Interval.Diabetes · 2025Trial
- The central role of the β-cell in diabetes: from monogenic forms to type 1, type 2, and gestational diabetes.Reviews in endocrine & metabolic disorders · 2026Review
- Reducing Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: The Impact of Screening Programs and Early Disease-Modifying Treatment.Journal of clinical medicine · 2026Review
- Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab.Diabetes care · 2026Review
- Ketoacidosis in new-onset type 1 diabetes: return to pre-COVID-19 pandemic reality?Pediatric endocrinology, diabetes, and metabolism · 2026Observational
- Latest Updates in Prevention and Screening of Type 1 Diabetes Mellitus.Current pediatrics reports · 2025Article
- Article
- Are We Ready With Prevention for Type 1 Diabetes?Diabetes/metabolism research and reviews · 2025Review
- Perspectives on prevention of type 1 diabetes and heterogeneities.Diabetologia · 2025Review
- Contrasting Adult and Pediatric Populations in a Cohort of At-Risk Relatives in The T1D TrialNet Pathway to Prevention Study.Diabetes care · 2025Article
- Effects of diabetic ketoacidosis, islet cell function, and age of onset on pancreas size, morphology, and exocrine function in children with type 1 diabetes: an abdominal MRI study.Journal of endocrinological investigation · 2025Article
- Prevalence of Islet Autoantibodies in Adults Without Diabetes.Journal of the Endocrine Society · 2025Article
- IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.Diabetologia · 2025Article
- Letter to the Editor From Papadimitriou: "Beyond Stages: Predicting Individual Time-dependent Risk for Type 1 Diabetes".The Journal of clinical endocrinology and metabolism · 2025Article
- Characteristics of autoantibody-positive individuals without high-risk HLA-DR4-DQ8 or HLA-DR3-DQ2 haplotypes.Diabetologia · 2025Article
- Epidemiological trends and risk factors of CKD-T1DM in children and adolescents across 204 countries and territories (1990-2021).Frontiers in endocrinology · 2025Article
- Disease-modifying therapies and features linked to treatment response in type 1 diabetes prevention: a systematic review.Communications medicine · 2023Article
- Diabetes and Dyslipidemia Screening in Pediatric Practice.Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
A diagnosis of type 1 diabetes (T1D) and the subsequent requirement for exogenous insulin treatment is associated with considerable acute and chronic morbidity and a substantial effect on patient quality of life. Importantly, a large body of work suggests that early identification of presymptomatic T1D can accurately predict clinical disease, and when paired with education and monitoring, can yield improved health outcomes. Furthermore, a growing cadre of effective disease-modifying therapies provides the potential to alter the natural history of early stages of T1D. In this mini review, we highlight prior work that has led to the current landscape of T1D screening and prevention, as well as challenges and next steps moving into the future of these rapidly evolving areas of patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.